Vera Therapeutics, Inc. Class A VERA 深 沪

Evercore ISI Group Maintains Outperform on Vera Therapeutics, Lowers Price Target to $91

Evercore ISI Group analyst Gavin Clark-Gartner maintains Vera Therapeutics (NASDAQ:VERA) with a Outperform and lowers the price target from $95 to $91.

今天 01:39

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics, Inc. announced on May 4, 2026, that its Compensation Committee granted inducement awards, including non-qualified stock options for 40,250 shares and RSUs for 20,125 shares, to 10 new employees under the 2024 Inducement Plan. The stock options have an exercise price of $35.51 per share, vesting over four years, with 25% on the first anniversary and the remainder monthly over 36 months. RSUs vest annually over four years. Vera T...

05-08 20:05

Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.34) by 26.12 percent. This is a 108.64 percent decrease over losses of $(0.81) per share

05-07 20:29

财报速睇 | Vera Therapeutics, Inc. Class A 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损1.21亿美元，同比亏损扩大132.7%

华盛资讯5月7日讯，Vera Therapeutics, Inc. Class A公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损1.21亿美元，同比亏损扩大132.7%。

05-07 20:14

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04-10 20:30

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics授予新任首席法律顾问Jane Wright-Mitchell股票期权和限制性股票单位（RSUs），总计101,253股A类普通股，以吸引其加入。期权行权价为每股40.73美元，基于2026年3月23日的收盘价，分四年归属。RSU则于2026年5月20日起每年归属25%，激励新员工长期服务。Vera是一家专注于开发免疫疾病治疗的临床后期生物科技公司，其主要候选药物atacicept针对多种自身免疫性疾病。

03-27 20:05

Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer

Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer Vera Therapeutics appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately. Wright-Mitchell previously served as a fractional general counsel supporting public and private life sciences companies. Her prior roles

03-25 19:30

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Vera Therapeutics appoints Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, leveraging her over 25 years of experience in legal and compliance matters within the life sciences industry. Her expertise will support Vera’s upcoming commercial launch of atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy, and strengthen the company’s legal framework. Wright-Mitchell previously served as General Counsel at Vaxcyte, Inc. and brings ...

03-25 11:30

美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级

今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元

03-12 12:34

Wolfe Research Upgrades Vera Therapeutics to Outperform, Announces $88 Price Target

Wolfe Research analyst Andy Chen upgrades Vera Therapeutics (NASDAQ:VERA) from Peer Perform to Outperform and announces $88 price target.

03-11 19:45